文章预览
SCI 6 September 2024 ZBTB46 coordinates angiogenesis and immunity to control tumor outcome (Nature Immunology, IF: 27.7) Ashraf Ul Kabir, Carisa Zeng, Madhav Subramanian, Jun Wu, Minseo Kim, Karen Krchma, Xiaoli Wang, Carmen M. Halabi, Hua Pan, Samuel A. Wickline, Daved H. Fremont, Maxim N. Artyomov & Kyunghee Choi CORRESPONDENCE TO: kchoi@wustl.edu Tumor angiogenesis and immunity show an inverse correlation in cancer progression and outcome. Here, we report that ZBTB46, a repressive transcription factor and a widely accepted marker for classical dendritic cells (DCs), controls both tumor angiogenesis and immunity. Zbtb46 was downregulated in both DCs and endothelial cells by tumor-derived factors to facilitate robust tumor growth. Zbtb46 downregulation led to a hallmark pro-tumor microenvironment (TME), including dysfunctional vasculature and immunosuppressive conditions. Analysis of human cancer data revealed a similar association of low ZBTB46 expression with an immunosuppressive
………………………………
